If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

Merc waves today with a $9.2% billion deal to acquire flu drug maker Sedara Therapeutics. Sedara shares more than doubling on the news. Well, Mercedes flat.The farmer giant is racing to replenish his pipeline ahead of Kitruda's 2028 patent expiry. The cancer drug accounted for nearly half of Merc's revenues in 2024. For more, let's bring in Missouo healthcare strategist Jared Holes.Jared, great to have you with us. Um, even prior to the deal, Sedera, that drug, it looked like it was going to be a blockbuste ...